Kidney cancer represents 2-3% of all cancers. Generally, during the last two decades until recently, there has been an annual increase of about 2% in incidence worldwide. The reason for this increase is unknown. Kidney cancer lacks specific symptoms. About half of kidney cancers were diagnosed incidentally by indeliberate imaging examination. The long-term oncological outcomes of kidney caners were closely related with stages. Therefore, the early detection and therapy of kidney cancer is the key point to improve its prognosis. However, there are no satisfactory biomarkers used for early detection, prognosis, and prediction of benefit from therapies, recurrence, or progression of kidney cancer. The basic researches of kidney cancer have given birth to some successful pharmaceutical products such as tyrosine kinase inhibitors (TKI) and m-TOR inhibitors, which have changed the treatment landscape for patients with metastatic kidney cancers. However, the vast majority of treated patients eventually develop progressive disease due to acquired resistance or other reasons. Hence, a better understanding of the mechanisms involved in the pathogenesis of kidney cancer and more effective therapeutic approaches are urgently required. The minimal invasive technologies have been widely used in treatment of kidney cancers. The outcomes of these novel therapeutic technologies are required to be presented to clinical workers in time. We invite investigators to contribute original research articles as well as review articles that focus on identification of new biomarkers, mechanisms, and new developments of minimal invasive technologies underlying kidney cancer.

Potential topics include, but are not limited to:

• Proteins, microRNA, lncRNA, tumor cells, and DNA in blood and urine as potential biomarkers for early detection, prognosis, and followup of kidney cancer
• The genetic/epigenetic events leading to the development and progression of kidney cancer
• New molecularly targeted agents
• Metabolism of kidney cancer, for example, lipid metabolism in kidney cancer cells
• Mechanism of resistance to targeted drugs such as TKI and m-TOR inhibitors in kidney cancer
• Tumor microenvironment in metastatic kidney cancer